Researchers say GLP-1 drugs prescribed for weight loss like Ozempic and Mounjaro are more effective at reducing heart health ...

BF Biosciences Limited has announced the commercial launch of Zeptide® (Tirzepatide), a next-generation therapy for Type 2 ...

Japanese drugmaker Chugai Pharmaceutical has concluded a license agreement with Roche for CT-388, a long-acting GLP-1/GIP ...

The European Association for the Study of Obesity (EASO) has called for GLP-1 agonists from Novo Nordisk and Eli Lilly to be ...

Researchers are exploring a novel quintuple agonist that targets five pathways, including GLP-1R, GIPR, and three PPARs. This innovative approach combines the benefits of incretin and PPAR pathways, ...

Chugai Pharma concludes license agreement with Roche for CT-388, a long-acting GLP-1/GIP receptor agonist: Tokyo Saturday, October 11, 2025, 11:00 Hrs [IST] Chugai Pharmaceutical ...

Evolv has launched a supplement featuring yeast engineered to produce a peptide that engages GLP-1 receptors, with a ...

"Type 2 diabetes in children and teens is increasing at an alarming rate, yet treatment options are limited, and this patient population remains underserved," said Kenneth Custer, Ph.D., executive ...

Two breakthrough diabetes drugs are reshaping the weight-loss landscape. Mounjaro and Ozempic are often compared, but experts ...

Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight In the trial, Mounjaro was associated ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized ...

Mounjaro, originally developed as a diabetes drug, has skyrocketed to become India’s no. 2 pharma brand, thanks to a booming ...